Alkaptonuria

For the why behind the fact

Use this page to connect what you are memorizing.

Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.

Overview


Plain-Language Overview

Alkaptonuria is an inherited condition in which the body cannot fully break down phenylalanine and tyrosine. Homogentisic acid (HGA) accumulates and can make urine darken after standing in air, sometimes from infancy. Over years, HGA-derived pigment builds up in connective tissues (ochronosis), causing dark patches in the eyes or ears and progressive spine/large-joint arthritis. Heart valves and the urinary tract may also be affected. Treatment aims to reduce HGA and manage symptoms and complications.

Clinical Definition

Alkaptonuria (AKU) is an autosomal recessive disorder caused by biallelic pathogenic variants in HGD, encoding homogentisate 1,2-dioxygenase (homogentisate oxidase). The blocked step is homogentisate → maleylacetoacetate in phenylalanine/tyrosine degradation. HGA accumulates, is excreted in urine, and oxidizes/polymerizes into ochronotic pigment in connective tissues. The classic triad is urine that darkens on standing, ochronosis, and degenerative arthropathy of the spine and large joints. Urinary findings can precede adult tissue disease by decades; quantify urinary HGA to establish the biochemical diagnosis.

Inciting Event

  • Inherited biallelic mutations in the HGD gene causing enzyme deficiency.

  • Onset of HGA accumulation begins at birth but clinical symptoms appear after years of deposition.

  • No external triggers; disease progression is due to endogenous metabolic defect.

  • Progressive oxidation of HGA leads to tissue pigmentation and damage over time.

  • Secondary joint stress and wear may exacerbate symptoms but do not initiate disease.

Latency Period

  • HGA overproduction/excretion is present from early life, but clinically apparent tissue ochronosis and joint disease often develop much later.

  • Spinal/joint symptoms often begin in the third or fourth decade, with variable onset and progression; biochemical disease precedes these symptoms.

  • Urine may darken from infancy after standing or alkalinization. This is a urinary oxidation phenomenon; ochronosis means pigment deposition in tissue.

  • Joint damage accumulates over years, with substantial variability; there is no fixed 10–20-year symptomatic latency.

  • Cardiac and renal complications manifest in late adulthood after prolonged pigment deposition.

Diagnostic Delay

  • Early symptoms such as dark urine are often overlooked or misattributed to benign causes.

  • Lack of awareness leads to misdiagnosis as osteoarthritis or other arthropathies.

  • Ochronotic pigmentation in cartilage and sclera may be missed without careful examination.

  • Biochemical testing for elevated urinary HGA is not routinely performed early.

  • Genetic testing for HGD mutations is underutilized in patients with suggestive symptoms.

Clinical Presentation


Signs & Symptoms

  • Urine that darkens on standing/exposure to air, sometimes noticed as dark diaper staining; freshly voided urine may look normal.

  • Progressive joint pain and stiffness typically beginning in the third to fourth decade

  • Bluish-black discoloration of sclera, ear cartilage, and skin over pressure areas

  • Early-onset degenerative arthritis affecting spine, hips, and knees

  • Cardiac valve calcification leading to murmurs or heart failure in advanced disease

History of Present Illness

  • Patients report darkening of urine upon standing since childhood, often unnoticed.

  • Progressive back and large-joint pain/stiffness often starts in early-to-middle adulthood; age of recognition varies.

  • Development of blue-black pigmentation of ear cartilage, sclera, and skin over time.

  • Symptoms of early-onset degenerative arthritis with decreased range of motion and joint swelling.

  • Possible history of cardiac valve disease or renal stones in advanced disease stages.

Past Medical History

  • No prior acute illnesses directly cause alkaptonuria but history may include early-onset osteoarthritis.

  • Possible history of recurrent renal stones due to HGA deposition.

  • Review nitisinone exposure, treatment response, eye symptoms and diet/monitoring, as well as analgesics and supplements. Vitamin C has no established disease-modifying benefit.

  • Ask about joint replacements, tendon procedures, valve surgery and renal/prostate stone interventions, as well as unrelated operations. Black cartilage may first be recognized during orthopedic surgery.

  • Ask about affected relatives, but a negative or unrecognized family history does not exclude recessive disease. Offer appropriate family evaluation after diagnosis.

Family History

  • An autosomal recessive pattern may include affected siblings or parental consanguinity, but absence of known affected relatives does not exclude AKU.

  • Relatives may have history of dark urine, early arthritis, or ochronosis.

  • Carrier parents are generally asymptomatic. When both are carriers, each pregnancy has a 25% affected, 50% carrier and 25% unaffected noncarrier probability; an affected child generally inherits one pathogenic allele from each parent.

  • Family members may have undergone joint replacements or have cardiac complications related to ochronosis.

  • Genetic counseling is important due to heritable nature of the disorder.

Physical Exam Findings

  • Bluish-black pigmentation of the sclera and ear cartilage due to homogentisic acid deposition

  • Darkening of urine upon standing or exposure to air from oxidation of homogentisic acid

  • Ochronotic pigmentation of connective tissues including skin, tendons, and cartilage

  • Restricted joint mobility and stiffness, especially in the spine and large joints

  • Degenerative arthritis signs such as joint swelling and tenderness in affected areas

Diagnostic Workup


Diagnostic Criteria

Establish the biochemical diagnosis by markedly elevated urinary HGA, measured by an appropriate organic-acid method such as GC-MS or LC-MS/MS. A random sample may detect elevation; quantification can use timed collection as indicated. Urine darkening, ochronosis and characteristic arthropathy support suspicion but are not substitutes for testing. Biallelic pathogenic/likely pathogenic HGD variants establish the molecular diagnosis and support family testing; variants of uncertain significance alone do not confirm or exclude AKU.

Pathophysiology


Key Mechanisms

  • Deficient homogentisate 1,2-dioxygenase blocks conversion of HGA to maleylacetoacetate, causing HGA accumulation and increased urinary excretion.

  • Excess HGA undergoes oxidation and polymerization, depositing as ochronotic pigment in connective tissues.

  • Pigment deposition causes degeneration and inflammation of cartilage, tendons, and other connective tissues.

  • Chronic oxidative damage from HGA contributes to progressive arthropathy and tissue dysfunction.

  • Renal and cardiac complications arise from HGA deposition in kidneys and heart valves.

InvolvementDetails
Organs

Joints are affected by ochronotic arthropathy leading to pain and stiffness

Heart valves may develop ochronotic pigmentation causing valvular disease

Kidneys can accumulate pigment leading to nephrolithiasis

Tissues

Cartilage undergoes ochronotic pigmentation and degeneration causing arthropathy

Connective tissue in skin and sclera shows dark pigmentation due to homogentisic acid deposits

Cells

Chondrocytes and the surrounding cartilage matrix are affected by HGA-derived pigment and oxidative injury, impairing cartilage structure and mechanical resilience.

Osteoclast-mediated remodeling may contribute to bone involvement; small mechanistic studies show altered osteoclastogenesis. The primary defect remains HGD deficiency, not a primary osteoclast disorder.

Chemical Mediators

Homogentisic acid accumulates due to homogentisate 1,2-dioxygenase deficiency causing tissue pigmentation

4-hydroxyphenylpyruvate dioxygenase is the enzyme inhibited by nitisinone to reduce homogentisic acid levels

Treatments


Pharmacological Treatments

  • Nitisinone

    • Mechanism:
      • Inhibits 4-hydroxyphenylpyruvate dioxygenase upstream of HGA formation, lowering HGA but raising plasma tyrosine. It does not replace the deficient HGD enzyme.

    • Side effects:
      • Elevated plasma tyrosine, a predictable consequence of upstream enzyme inhibition; painful palm/sole hyperkeratotic lesions may occur.

      • Keratopathy/keratitis, eye pain, photophobia or corneal changes; obtain baseline and regular slit-lamp examinations and promptly assess new ocular symptoms.

      • Thrombocytopenia or leukopenia: monitor platelets and white blood cell counts.

    • Clinical role:
      • Specialist-supervised HGA-lowering treatment in adults with AKU. US Harliku is approved to reduce urinary HGA; European Orfadin also has an adult AKU indication, and trial evidence supports slower clinical progression. It is not a cure or assured reversal of established arthritis. Follow the specific product/regional regimen; pediatric AKU efficacy and safety are not established in these labels.

Non-pharmacological Treatments

  • Use metabolic-dietitian guidance rather than unsupervised protein restriction. Dietary phenylalanine/tyrosine restriction alone has not shown reliable clinical benefit for AKU; it may be used to manage nitisinone-associated elevated tyrosine/keratopathy, while preserving adequate nutrition.

  • Physical therapy to maintain joint mobility and reduce stiffness

  • Surgical joint replacement for severe ochronotic arthropathy

Prevention


Pharmacological Prevention

  • Nitisinone reduces ongoing HGA production and can slow progression in treated adults; it does not prevent inheritance or replace rehabilitation and complication surveillance.

  • Vitamin C has no established clinical efficacy for preventing ochronosis or arthropathy and should not be presented as disease-modifying treatment.

Non-pharmacological Prevention

  • Maintain adequate nutrition. Routine severe protein restriction is not a proven prevention strategy; the US Harliku label does not require routine restriction, but targeted tyrosine/phenylalanine restriction may be needed for treatment-related keratopathy.

  • Use physical/occupational therapy and low-impact exercise to preserve strength, flexibility and function; these measures do not stop HGA production.

  • Assess complications with specialist follow-up: echocardiographic surveillance after about age 40, earlier for symptoms; monitor renal function and investigate stone symptoms. Check thyroid function at diagnosis and periodically. Routine repeated urinary-tract imaging is not automatically required in every asymptomatic patient.

  • Avoidance of trauma to joints and tendons to prevent exacerbation of ochronotic damage

Outcome & Complications


Complications

  • Severe ochronotic arthropathy leading to chronic pain and disability

  • Valvular heart disease from pigment deposition and calcification

  • Urinary stones, obstruction and renal impairment may complicate AKU. Reduced kidney function also impairs HGA elimination and can accelerate systemic pigment accumulation.

  • Rare compressive myelopathy can result from severe degenerative/calcific spinal disease; new weakness, gait change or sphincter symptoms require evaluation.

Short-term Sequelae Long-term Sequelae
  • Acute joint pain flares due to inflammation in ochronotic arthropathy

  • Urine darkening itself does not cause acute injury, but it is a clue to an underlying metabolic disorder and warrants evaluation when unexplained.

  • Tendon inflammation or rupture causing acute musculoskeletal symptoms

  • Chronic degenerative arthritis with joint deformities and limited mobility

  • Progressive cardiac valvular disease potentially requiring surgical intervention

  • Permanent pigmentation changes in connective tissues and skin

  • Renal dysfunction can occur, particularly with urinary complications; declining clearance can further raise HGA. Chronic kidney disease is not inevitable in every patient.

Differential Diagnoses


Alkaptonuria versus Ochronosis secondary to exogenous ochronotic pigment

Alkaptonuria

Ochronosis secondary to exogenous ochronotic pigment

Biallelic HGD deficiency causes endogenous HGA excess; an unrelated exposure history does not exclude AKU.

Usually a history of prolonged hydroquinone or related chemical exposure, often affecting treated skin.

Markedly elevated urinary HGA establishes the biochemical abnormality; urine darkening is only a clue.

Exogenous ochronosis does not itself produce the marked urinary HGA elevation of AKU; assess exposure and skin findings.

Systemic HGA excess may cause connective-tissue pigment, arthropathy, valve disease and urinary complications.

Typically an acquired cutaneous pigment disorder, without the inherited HGA-overproduction syndrome or its usual systemic course.

Alkaptonuria versus Rheumatoid arthritis

Alkaptonuria

Rheumatoid arthritis

Biochemical abnormalities begin early, but spine and large-joint arthropathy usually becomes evident in adulthood; small joints are less commonly affected.

Persistent inflammatory synovitis often affects small joints of the hands/feet, frequently symmetrically, with prolonged morning stiffness; adult onset spans a broad age range.

Disc calcification/narrowing and degenerative large-joint changes support ochronotic arthropathy; plain radiographs do not directly show pigment color.

Symmetric joint-space loss and marginal erosions may develop; early RA radiographs may be normal, with ultrasound/MRI identifying inflammation earlier.

Elevated urinary HGA is the defining biochemical finding; RF/anti-CCP negativity is not an AKU requirement.

RF/anti-CCP can support RA, but seronegative RA exists and positive RF is not specific. Interpret with persistent synovitis.

Alkaptonuria versus Ankylosing spondylitis

Alkaptonuria

Ankylosing spondylitis

Marked intervertebral-disc calcification/narrowing with relative sacroiliac sparing is typical.

Sacroiliitis and syndesmophytes support radiographic axial SpA; bamboo spine is a late finding. MRI may identify inflammatory changes when radiographs are nondiagnostic.

Diagnosis relies on urinary HGA/HGD findings, not HLA-B27 negativity.

HLA-B27 supports suspicion in the right context, but negative testing does not exclude SpA and positivity alone is not diagnostic.

Progressive degenerative joint disease with ochronotic pigmentation

Chronic inflammatory back pain improving with exercise

Alkaptonuria versus Hemochromatosis

Alkaptonuria

Hemochromatosis

Marked urinary HGA supports AKU; iron studies are not diagnostic of AKU and can be abnormal for other reasons.

Persistent transferrin-saturation/ferritin elevation warrants iron-overload assessment with appropriate genetics and clinical context; ferritin alone is nonspecific.

Disc calcification/degenerative joint changes support ochronotic arthropathy; cardiac and urinary complications may also occur.

MRI can quantify hepatic iron when indicated; additional organ assessment depends on the phenotype. Not all patients have iron loading in every organ.

AKU is systemic, with joints, connective tissues, valves and the urinary tract potentially affected.

Iron overload may cause liver disease, diabetes, cardiomyopathy and arthropathy; urinary HGA excess is not its defining abnormality.

Alkaptonuria versus Paget disease of bone

Alkaptonuria

Paget disease of bone

Urinary HGA excess begins in early life, while recognizable arthropathy usually develops in adulthood.

Typically affects older adults, particularly after age 50; age supports context rather than providing a definitive test.

Disc calcification/narrowing and degenerative arthropathy are typical; pigment color is not directly visible on a plain radiograph.

Focal bone expansion, cortical thickening and mixed lytic/sclerotic change favor Paget disease; imaging defines involvement.

Urinary HGA is the diagnostic biochemical marker; ALP may vary with other bone or liver conditions.

ALP is often elevated in active disease but can be normal in limited/monostotic disease; use imaging and, when needed, bone-specific markers.